Lidocaine intradermal - Anesiva

Drug Profile

Lidocaine intradermal - Anesiva

Alternative Names: ALGRX 3268; D-4115; Lidocaine microcrystals; PowderJect Dermal Lignocaine; PowderJect Lidocaine; Zingo

Latest Information Update: 22 Feb 2016

Price : $50

At a glance

  • Originator Anesiva
  • Developer Anesiva; Marathon Pharmaceuticals
  • Class Acetanilides; Class Ib antiarrhythmics; Local anaesthetics; Small molecules
  • Mechanism of Action Opioid receptor agonists; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Anaesthesia

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 01 Sep 2015 Efficacy and adverse events data from a phase III trial in Anaesthesia released by Marathon Pharmaceuticals
  • 17 Jun 2015 Tribute Pharmaceuticals Canada acquires Medical Futures
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top